Iradimed Corp (IRMD)
NASDAQ:IRMD
Want to see IRMD full AI Analyst Report?
IRMD Stock Chart & Stats
$76.42
$0.29(0.51%)
At close: 4:00 PM EST
$76.42
$0.29(0.51%)
Day’s Range― - ―
52-Week Range$55.11 - $107.90
Previous CloseN/A
Volume15.52K
Average Volume (3M)137.04K
Market Cap
$1.17B
Enterprise Value$1.11B
Total Cash (Recent Filing)$56.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)49.3
Beta0.63
Next Earnings
Jul 30, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend Yield1.22%
Share Statistics
EPS (TTM)1.86
Shares Outstanding12,783,035
10 Day Avg. Volume158,387
30 Day Avg. Volume137,043
Financial Highlights & Ratios
PEG Ratio3.35
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue12.84
Enterprise Value/Gross Profit16.71
Enterprise Value/Ebitda34.38
Forecast
1Y Price Target
$116.00Price Target Upside51.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.08
Revenue Forecast (FY)$91.75M
Bulls Say, Bears Say
Bulls Say
High And Improving ProfitabilitySustained high gross and operating margins indicate durable product pricing power and low incremental production costs for MRI‑compatible devices. This margin profile supports reinvestment, healthy cash conversion when stable, and resilience to moderate revenue swings over the next several months.
Conservative Balance Sheet With Minimal DebtNear‑zero leverage and strong ROE give management flexibility to fund manufacturing scale, M&A, or R&D from cash rather than debt. This reduces solvency risk, limits refinancing exposure, and supports stable dividends and capex funding across a 2–6 month horizon.
Promising 3870 Product Launch & RunwayThe 3870 offers a structural growth vector: higher ASPs and larger multi‑channel unit adoption can expand per‑order economics and recurring consumables. If sustained, this product-driven uplift supports a multi-quarter acceleration in installed base and attach revenue streams.
Bears Say
Manufacturing Ramp And Execution RiskConstrained production capacity and conservative ramping can defer revenue recognition and delay realization of higher ASPs and attach sales. Execution shortfalls in scale‑up could compress near‑term growth and test operational margins over several quarters as demand outpaces supply build.
Geographic Concentration And Limited AdjacenciesHeavy U.S. concentration and flat consumables constrain revenue diversification. Reliance on a single geography increases exposure to domestic hospital capital cycles and policy changes, while slow adjacencies limit near‑term upside from consumables and small product lines.
Revenue Variability And Cash Conversion VolatilityInconsistent top‑line cadence and episodic working‑capital swings indicate that free‑cash‑flow may vary materially quarter‑to‑quarter. This volatility can complicate reinvestment timing, dividend sustainability, and the pace of manufacturing or sales scaling over the medium term.
Iradimed News
IRMD FAQ
What was Iradimed Corp’s price range in the past 12 months?
Iradimed Corp lowest stock price was $55.11 and its highest was $107.90 in the past 12 months.
What is Iradimed Corp’s market cap?
Iradimed Corp’s market cap is $1.17B.
When is Iradimed Corp’s upcoming earnings report date?
Iradimed Corp’s upcoming earnings report date is Jul 30, 2026 which is in 42 days.
How were Iradimed Corp’s earnings last quarter?
Iradimed Corp released its earnings results on May 01, 2026. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.445 by $0.045.
Is Iradimed Corp overvalued?
According to Wall Street analysts Iradimed Corp’s price is currently Undervalued.
Does Iradimed Corp pay dividends?
Iradimed Corp pays a Monthly dividend of $0.2 which represents an annual dividend yield of 1.22%. See more information on Iradimed Corp dividends here
What is Iradimed Corp’s EPS estimate?
Iradimed Corp’s EPS estimate is 0.44.
How many shares outstanding does Iradimed Corp have?
Iradimed Corp has 12,783,035 shares outstanding.
What happened to Iradimed Corp’s price movement after its last earnings report?
Iradimed Corp reported an EPS of $0.49 in its last earnings report, beating expectations of $0.445. Following the earnings report the stock price went up 4.447%.
Which hedge fund is a major shareholder of Iradimed Corp?
Currently, no hedge funds are holding shares in IRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iradimed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$116.00 (51.79% Upside)
$116.00 (51.79% Upside)
Blogger Sentiment
Bullish
IRMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 11.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $285.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.12%
12-Months-Change
Fundamentals
Return on Equity
24.48%
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
Iradimed Corp
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
IRMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive outlook driven by strong Q1 financial results (13% revenue growth, 33% operating income growth, double-digit net income improvement), healthy margins, substantial cash generation, and an encouraging early 3870 product launch with higher-than-expected ASP and quad-system demand. Near-term headwinds are primarily transitional and execution-related: a planned conservative manufacturing ramp (130–135 3870s in Q2) leads to guidance showing a modest Q2 revenue dip versus Q1, and there are temporary tax and R&D expense effects. These lowlights appear manageable relative to the magnitude of the reported financial improvements and the sizeable replacement opportunity for the 3870, so positive momentum is the dominant theme.View all IRMD earnings summariesIRMD Stock 12 Month Forecast
Average Price Target
$116.00
▲(51.79% Upside)
Technical Analysis
Ownership Overview
34.84% Insiders
12.55% Mutual Funds
18.01% Other Institutional Investors
25.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---